Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA35 in Myofascial Pain Syndrome
NCT06444035Completed
- Sponsor
- Nakhia Impex LLC
- Start
- May 2024
- Primary completion
- Oct 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of ha35 in myofascial pain syndrome (MPS), sponsored by Nakhia Impex LLC. Primary endpoint: Chronic myofascial pain score at 90 days. Started May 2024; status: completed.
02
Drugs
ha35
03
Conditions
myofascial pain syndrome (MPS)
Beyond the preview
Go deeper on NCT06444035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444035.